Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report)’s stock price shot up 7.8% on Thursday . The stock traded as high as $0.20 and last traded at $0.19. 19,100 shares were traded during trading, a decline of 88% from the average session volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Trading Up 7.8 %
The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.86 and a current ratio of 2.86. The company has a 50-day simple moving average of $0.19 and a two-hundred day simple moving average of $0.18.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Vyant Bio stock. US Bancorp DE increased its holdings in shares of Vyant Bio, Inc. (OTCMKTS:VYNT – Free Report) by 3,001.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,813 shares of the company’s stock after acquiring an additional 24,013 shares during the quarter. US Bancorp DE owned about 0.08% of Vyant Bio worth $35,000 as of its most recent SEC filing.
Vyant Bio Company Profile
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
Recommended Stories
- Five stocks we like better than Vyant Bio
- Overbought Stocks Explained: Should You Trade Them?
- Comprehensive PepsiCo Stock Analysis
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Energy and Oil Stocks Explained
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.